Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

GNE-309 - a novel BTK inhibitor for the treatment of rheumatoid arthritis

April 9, 2015

Cytori Therapeutics' ECCS-50 receives E.U. orphan drug designation for scleroderma

April 8, 2015

GlaxoSmithKline's SARM for muscle wasting diseases

April 8, 2015

Pharmalink acquires osteoarthritis candidate from Synartro

March 19, 2015

GSK plans first-in-human study of GSK-2330811 for inflammatory and fibrotic diseases

March 18, 2015

Samsung Bioepis submits MAA to EMA for Remicade biosimilar

March 16, 2015

Corbus Pharmaceuticals receives IND clearance from FDA to begin phase II trials of Resunab

March 13, 2015

Medtronic invests in Flex Pharma IPO

March 6, 2015

Cadila Healthcare patents new JAK inhibitors

March 3, 2015

Ampio reports results from phase II portion of STRUT study of Ampion in OA

Feb. 27, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...